Pfizer announcing promising results About ( covid-19 )

Pfizer announcing promising results About ( covid-19 ). Pfizer’s, are a boost for a new approach to vaccine design. Recently, American pharma company Pfizer has claimed that its vaccine candidate BNT162b2 is more than 90% effective in preventing Covid-19 in participants without evidence of prior SARS-CoV-2 infection. The m-RNA class of vaccines are a synthetic construction of a piece of genetic machinery that viruses need to replicate. There are twin advantages. No physical part of a virus is introduced, reducing the odds of adverse reactions, and the number of doses can be quickly scaled up as they do not need mammalian cells.

Unlike traditional vaccines, which work by training the body to recognize and kill proteins produced by pathogens, mRNA tricks the patient’s immune system to produce viral proteins itself. Pfizer, announcing promising results from its ongoing phase-3 trial of a potential COVID-19 vaccine, Modern, the U.S.-based biotechnology firm, has indicated similar news from human trials (again phase 3) of its m-RNA vaccine. The mRNA vaccine is a new approach to protecting against viral infection. This is a sign that the vaccine is successful in its primary job of protection though its efficacy at curbing disease transmission is still to be evaluated. Pfizer announcing promising results About ( covid-19 )

Under this arrangement, the member-countries, and this includes India, are in line to get a minimum number of doses, however few, to cover a fraction of their population on priority basis. In phase 3 clinical trial began in July with 43,538 participants, 38,955 of whom had received a second dose by November. And The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at 7 days after the second dose.

It’s like Modern says it can ready 20 million doses by the year end. By late next year, this can be ramped up to the billions but by then it is expected that several more vaccines that are in large trials, including those in India, will be available. And the India does not stand to directly and immediately gain significantly from Modern. As per research However, every vaccine candidate that passes a significant hoop is a win for the world as it opens the way to new practices and ways of applying science that would have been otherwise implausible in the pre-pandemic world. The Pfizer has become the first firm to release promising late-stage trial data of a potential vaccine for Covid-19, even though the announcement does not have scientifically conclusive evidence on the safety and efficacy of the vaccine candidate.

Post a Comment

Target / Unique Batch - 2020

G.S. Foundation Batch 2021-22, 23

Call Us for 100% Scholarship

( 12th pass & Undergraduate )

2-3 Year Programme

Fillup Scholarship Form : Click Here
Online Pay and Reserve Your Seat : Click Here